- Home
- IFRX vs VTVT Comparison
IFRX vs VTVT Comparison
Compare IFRX & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- VTVT
- Stock Information
- Founded
- IFRX 2007
- VTVT 2015
- Country
- IFRX Germany
- VTVT United States
- Employees
- IFRX N/A
- VTVT N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- IFRX Health Care
- VTVT Health Care
- Exchange
- IFRX Nasdaq
- VTVT Nasdaq
- Market Cap
- IFRX 65.8M
- VTVT 56.7M
- IPO Year
- IFRX 2017
- VTVT 2015
- Fundamental
- Price
- IFRX $1.69
- VTVT $21.03
- Analyst Decision
- IFRX Strong Buy
- VTVT Strong Buy
- Analyst Count
- IFRX 4
- VTVT 2
- Target Price
- IFRX $8.50
- VTVT $35.50
- AVG Volume (30 Days)
- IFRX 262.5K
- VTVT 8.6K
- Earning Date
- IFRX 05-07-2025
- VTVT 05-15-2025
- Dividend Yield
- IFRX N/A
- VTVT N/A
- EPS Growth
- IFRX N/A
- VTVT N/A
- EPS
- IFRX N/A
- VTVT N/A
- Revenue
- IFRX $140,242.00
- VTVT $1,017,000.00
- Revenue This Year
- IFRX $61.96
- VTVT N/A
- Revenue Next Year
- IFRX $80.59
- VTVT N/A
- P/E Ratio
- IFRX N/A
- VTVT N/A
- Revenue Growth
- IFRX 30.90
- VTVT N/A
- 52 Week Low
- IFRX $0.82
- VTVT $12.12
- 52 Week High
- IFRX $2.82
- VTVT $29.01
- Technical
- Relative Strength Index (RSI)
- IFRX 62.40
- VTVT 52.66
- Support Level
- IFRX $1.53
- VTVT $20.12
- Resistance Level
- IFRX $1.92
- VTVT $22.41
- Average True Range (ATR)
- IFRX 0.19
- VTVT 1.34
- MACD
- IFRX 0.02
- VTVT -0.09
- Stochastic Oscillator
- IFRX 74.59
- VTVT 48.48
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.